Jubilant Pharmova Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment engages in the manufacturing and supply of allergy therapy products, contract manufacturing of sterile injectables and non-sterile products, active pharmaceutical ingredients, and solid dosage formulations, as well as sale of radiopharmaceuticals through a network of 48 radio pharmacies in the United States. The Contract Research & Development Services segment provides collaborative research services to pharmaceutical innovators. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune disorders. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is headquartered in Noida, India.
Revenue of Jubilant Pharmova Limited (JUBLPHARMA.NS)
Revenue in 2023 (TTM): $793.83 M
According to Jubilant Pharmova Limited's latest financial reports the company's current revenue (TTM) is $793.83 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Jubilant Pharmova Limited
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $793.83 M | $232.63 M | $94.82 M | $20.19 M | $9.13 M |
| 2022 | $736.55 M | $514.15 M | $89.74 M | $3.29 M | $-7,221,878 |
| 2021 | $717.59 M | $505.96 M | $138.28 M | $74.66 M | $49.02 M |
| 2020 | $706.3 M | $498.64 M | $164.96 M | $103.16 M | $98.99 M |
| 2019 | $1.06 B | $653.98 M | $183.85 M | $143.36 M | $106.38 M |
| 2018 | $1.07 B | $612.98 M | $176.85 M | $107.04 M | $68.03 M |
| 2017 | $879.32 M | $507.03 M | $173.68 M | $101.74 M | $76.13 M |
| 2016 | $682.78 M | $416.06 M | $161.75 M | $87.36 M | $68.17 M |
| 2015 | $675.11 M | $394.32 M | $146.75 M | $69.2 M | $51.1 M |
| 2014 | $684.07 M | $338.44 M | $82.41 M | $4.78 M | $-6,841,006 |
| 2013 | $677.61 M | $359.39 M | $121.96 M | $24.55 M | $12.91 M |
| 2012 | $609.09 M | $366.3 M | $99.05 M | $40.4 M | $18.09 M |
| 2011 | $509.62 M | $245.31 M | $66.39 M | $13.51 M | $1.72 M |
| 2010 | $406.62 M | $244.43 M | $63.87 M | $28.49 M | $27.21 M |
| 2009 | $447.82 M | $87.1 M | $93.93 M | $61.33 M | $49.91 M |
| 2008 | $416.64 M | $222.47 M | $67.13 M | $35.12 M | $33.54 M |
| 2007 | $294.76 M | $156.3 M | $70.4 M | $54.02 M | $47.43 M |
| 2006 | $214.33 M | $99.57 M | $47.97 M | $34.97 M | $27 M |
| 2005 | $178.28 M | $25.7 M | $28.32 M | $19.91 M | $15.36 M |
| 2004 | $138.59 M | $60.29 M | $26.72 M | $19.44 M | $14.12 M |
| 2003 | $101.76 M | $49.89 M | $19.38 M | $11.44 M | $9.27 M |